Award Type [Axis]
Equity Option [Member]
Employee Stock Purchase Plan [Member]
Class of Stock [Axis]
Common Stock
Series E Preferred Stock [Member]
Preferred Stock
Concentration Risk Type [Axis]
Halozyme Therapeutics, Inc [Member]
Coherus Biosciences, Inc.
Other Customers
Coherus Biosciences, Inc. [Member]
Antidilutive Securities [Axis]
Stock Options
Stock Conversion Description [Axis]
If Converted Method [Member]
Stock Options [Member]
Warrants
Option, Warrants, Series E Preferred Stock [Member]
Concentration Risk Benchmark [Axis]
Accounts Receivable [Member]
Customer [Axis]
Six Customers [Member]
Property Subject to or Available for Operating Lease [Axis]
Lease 1 [Member]
Lease 2 [Member]
Lease 3 [Member]
Lease 4 [Member]
Transaction Type [Axis]
June 13, 2014 Financing [Member]
August 7, 2015 Financing [Member]
Equity Distribution Agreement August 7, 2015 [Member]
Common Stock Purchase Agreement October 30, 2015 [Member]
EquityAug2015Member
Dividends [Axis]
Fiscal Year 2016, Qtr 1 [Member]
Fiscal Year 2016, Qtr 2 [Member]
Fiscal Year 2016, Qtr 3 [Member]
Fiscal Year 2016, Qtr 4 [Member]
Fiscal Year 2016 [Member]
Fiscal Year 2017, Qtr 1 [Member]
Fiscal Year 2017, Qtr 2 [Member]
Fiscal Year 2017, Qtr 3 [Member]
Fiscal Year 2017, Qtr 4 [Member]
Fiscal Year 2017 [Member]
Fiscal Year 2018, Qtr 1 [Member]
Fiscal Year 2018, Qtr 2 [Member]
Fiscal Year 2018, Qtr 3 [Member]
Fiscal Year 2018, Qtr 4 [Member]
Fiscal Year 2018 [Member]
June 2014 AMI Agreement
August 2015 AMI Sales Agreement [Member[
Equity Distribution Agreement [Member]
Common Stock Purchase Agreement [Member]
Income Statement Location [Axis]
Cost of contract manufacturing
Selling, general and administrative
Discontinued operations
Stock Option [Member]
Share-based awards [Member]
Stock Incentive Plans [Member]
Income Tax Authority [Axis]
Domestic Country [Member]
State and Local Jurisdiction [Member]
Restructuring Type [Axis]
Restructuring [Member]
Segments [Axis]
Contract Manufacturing Services Segment [Member]
Research and Development Segment [Member]
Operating Activities [Axis]
Discontinued Operations [Member] [Default Label]
Equity Components [Axis]
Additional Paid-In Capital
Accumulated Deficit
February 14, 2018 Public Offering [Member]
October 30, 2015 Financing [Member]
Research and Development Expense [Member]
Selling, General and Administrative Expenses [Member]
Restructuring Charges [Member]
Options and ESPP [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Trade and other receivables
Inventories
Prepaid expenses
Assets of discontinued operations
Total current assets
PROPERTY AND EQUIPMENT:
Leasehold improvements
Laboratory equipment
Furniture, fixtures, office equipment and software
Construction-in-progress
Property and equipment, gross
Less accumulated depreciation and amortization
Property and equipment, net
Restricted cash
Other assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable
Accrued payroll and related costs
Deferred revenue
Customer deposits
Other current liabilities
Liabilities of discontinued operations
Total current liabilities
Deferred rent, less current portion
Commitments and contingencies (Note 3)
STOCKHOLDERS' EQUITY:
Preferred stock - $.001 par value; authorized 5,000,000 shares; 1,647,760 shares issued and outstanding at April 30, 2018 and 2017, respectively
Common stock - $.001 par value; authorized 500,000,000 shares; 55,689,222 and 44,014,040 shares issued and outstanding at April 30, 2018 and 2017, respectively
Additional paid-in-capital
Accumulated deficit
Total stockholders' equity
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Preferred stock par value (in Dollars per share)
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock par value (in Dollars per share)
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Contract manufacturing revenue
Cost of contract manufacturing
Gross profit (loss)
Operating expenses:
Selling, general and administrative
Restructuring charges
Total operating expenses
Operating income (loss)
Other income (expense):
Interest and other income
Interest and other expense
Income (loss) from continuing operations
Loss from discontinued operations
Net Loss
Comprehensive loss
Series E preferred stock accumulated dividends
Net loss attributable to common stockholders
Basic and diluted weighted average common shares outstanding
Basic and diluted net loss per common share attributable to common stockholders - Continuing operations
Basic and diluted net loss per common share attributable to common stockholders - Discontinued operations
Net loss per share attributable to common stockholders
Statement [Table]
Statement [Line Items]
Beginning balance, shares
Beginning balance, value
Series E preferred stock issued for cash, net of issuance costs, shares
Series E preferred stock issued for cash, net of issuance costs, value
Series E preferred stock dividends
Cumulative-effect adjustment to accumulated deficit
Common stock issued for cash, net of issuance costs, shares
Common stock issued for cash, net of issuance costs, value
Common stock issued for cash, net of issuance costs, shares
Common stock issued for cash, net of issuance costs, value
Common stock issued for cash, net of issuance costs, shares
Common stock issued for cash, net of issuance costs, value
Common stock issued for cash, net of issuance costs, shares
Common stock issued for cash, net of issuance costs, value
Common stock issued for cash under Public Offering, net of issuance costs, Shares
Common stock issued for cash under Public Offering, net of issuance costs, Value
Common stock issued under Employee Stock Purchase Plan, shares
Common stock issued under Employee Stock Purchase Plan, value
Common stock issued upon exercise of options, shares
Common stock issued upon exercise of options, value
Fractional shares issued pursuant to reverse stock split
Share-based compensation
Net loss
Ending balance, shares
Ending balance, value
Issuance costs
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
Depreciation and amortization
Loss on disposal of property and equipment and other assets
Gain on sale of research and development assets
Changes in operating assets and liabilities:
Trade and other receivables
Inventories
Prepaid expenses
Restricted cash
Other non-current assets
Accounts payable
Accrued clinical trial and related fees
Accrued payroll and related costs
Deferred revenue
Customer deposits
Other accrued expenses and current liabilities
Deferred rent, less current portion
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment acquisitions
Decrease in other assets
Proceeds from sale of research and development assets
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs of $1,780,000, $827,000, and $677,000, respectively
Proceeds from issuance of Series E preferred stock, net of issuance costs of nil, $58,000, and $1,000, respectively
Proceeds from issuance of common stock under Employee Stock Purchase Plan
Proceeds from exercise of stock options
Dividends paid on preferred stock
Principal payments on capital leases
Net cash provided by financing activities
NET DECREASE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
SUPPLEMENTAL INFORMATION:
Cash paid for interest
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accounts payable and other liabilities for purchase of property and equipment and other assets
Other receivables related to the sale of research and development assets
Property and equipment acquired under capital lease
Lease incentives
Stock Issuance costs
Organization And Business Description
ORGANIZATION AND BUSINESS DESCRIPTION
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Equity [Abstract]
STOCKHOLDERS' EQUITY
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
7. EQUITY COMPENSATION PLANS
Warrants and Rights Note Disclosure [Abstract]
WARRANTS
Income Tax Disclosure [Abstract]
INCOME TAXES
Restructuring Costs [Abstract]
Restructuring
Discontinued Operations and Disposal Groups [Abstract]
SALE OF RESEARCH AND DEVELOPMENT ASSETS
Retirement Benefits [Abstract]
BENEFIT PLAN
Quarterly Financial Information Disclosure [Abstract]
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of Presentation
Use of Estimates
Discontinued Operations
Segment Reporting
Going Concern
Reclassification
Restructuring
Cash and Cash Equivalents
Restricted cash
Trade and Other Receivables
Allowance for Doubtful Accounts
Inventories
Property and Equipment, net
Concentrations of Credit Risk and Customer Base
Comprehensive Loss
Impairment
Fair Value of Financial Instruments
Fair Value Measurements
Customer Deposits
Deferred Rent
Revenue Recognition
Share-based Compensation
Income Taxes
Basic and Dilutive Net Loss Per Common Share
Recently Adopted Accounting Pronouncements
Pending Adoption of Recent Accounting Pronouncements
Trade and Other Receivables
Inventories
Customer Revenue
Antidilutive Shares
Schedule of operating leases
Future minimum lease payments under all non-cancelable operating leases
Schedule of stock issued under financing transactions
Schedule of preferred stock dividends
Fair value valuation assumptions
Schedule of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table Text Block
Schedule of stock option transaction activity
Share-based compensation expense
Provision for income taxes
Deferred income taxes
Discontinued operations summary
Selected quarterly financial information for each of the two most recent fiscal
Trade receivables
Other receivables
Trade and other receivables
Raw materials
Work-in-process
Finished goods
Total inventories
Customer revenue as a percentage of revenue
Dilutive effect of shares on diluted shares outstanding
Subsequent Event Type [Axis]
Restricted cash pledged as collateral
Allowance for doubtful accounts - other receivables
Idle capacity costs
Estimated useful lives of property and equipment
Concentration risk percentage
Number of buildings occupied
Initial lease term expiration date
Number of options to extend lease
Extended lease term expiration date
2019
2020
2021
2022
2023
Thereafter
Operating Leases, Future Minimum Payments Due
Annual rent expense
Number of common stock shares issued, shares
Gross proceeds from the sale of common stock
Declaration Date
Record date
Payment date
Total dividends paid
Dividend per share
Aggregate gross proceeds available in offering
Series E preferred stock issued for cash, shares
Series E preferred stock issued for cash, value
Risk-free interest rate
Expected life (in years)
Expected volatility
Expected dividend yield
Number of Options
Number of Options Outstanding, Beginning
Number of Options Granted
Number of Options Exercised
Number of Options Cancelled or Expired
Number of Options Outstanding, Ending
Exercisable and expected to vest
Exercisable at period end
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding, Beginning
Weighted Average Exercise Price Granted
Weighted Average Exercise Price Exercised
Weighted Average Exercise Price Canceled
Weighted Average Exercise Price Outstanding, Ending
Weighted Average Exercise Price, Exercisable and expected to vest
Weighted Average Exercise Price Exercisable, at period end
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years) Outstanding
Weighted Average Remaining Contractual Life (in years) Vested and expected to vest
Weighted Average Remaining Contractual Life (in years) Exercisable, at period end
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding
Aggregate Intrinsic Value vested and expected to vest
Aggregate Intrinsic Value Exercisable at period end
Share based compensation
Counterparty Name [Axis]
Common shares reserved for issuance
Shares available for purchase
Stock issued during period, ESPP
ESPO weighted average purchase price
Weighted-average grant date fair value of options granted
Aggregate intrinsic value of stock options exercised
Cash received from stock options exercised
Unrecognized compensation costs related to non-vested stock options
Unrecognized compensation cost weighted average vesting period
Weighted average grant date fair value, other than options
Warrants outstanding
Warrants outstanding exercise price
Warrants issued
Warrants exercised
Warrants exercisable through date
Federal income taxes at statutory rate
State income taxes
Expiration and adjustments of deferred tax assets
Change in valuation allowance
Share-based compensation
Other, net
Tax Cuts and Jobs Act
Income tax (expense) benefit
Share-based compensation
Deferred revenue
Deferred rent
Other
Net operating losses
Total deferred tax assets
Less valuation allowance
Net deferred tax assets
Deferred tax liabilities:
Fixed assets
Total deferred tax liabilities
Net deferred tax assets
Unrecognized tax benefits from uncertain tax positions
Income tax penalties or interest
Income tax penalties or interest accrued
Net operating loss carry forward
Operating loss carryforward expiration dates
U.S. corporate income tax rate
Workforce reduction
Aggregate restructuring costs
License revenue
Total operating expenses
Other income
Gain on sale of research and development assets
Assets:
Other receivables
Property and equipment, net
Other assets
Total assets of discontinued operations
Liabilities:
Accounts payable
Accrued clinical trial and related fees
Other liabilities
Total liabilities of discontinued operations
Proceeds from sale of business segment
Terms of sale
Matching contributions
Contract manufacturing revenue
Gross profit
Income (loss) from continuing operations
Income (loss) from discontinued operations
Net income (loss)
Series E preferred stock accumulated dividends
Net income (loss) attributable to common stockholders
Aggregate gross proceeds available in offering
Aggregate Intrinsic Value heading
Amounts remaining under registration statements
Custom Element.
Customer Deposits [Policy Text Block]
Custom Element.
Custom Element.
Custom Element.
Extended lease term expiration date assumes we execute all available option(s) to extend lease in accordance with the terms of the lease agreement.
Lease incentives available to lessee from the lessor under an operating lease but not yet incurred.
Number of options to extend lease term.
Operating loss carryforward expiration dates
Other Customers Member
Series E preferred stock issued for cash, net of issuance costs, shares
Series E preferred stock issued for cash, net of issuance costs, value
Proceeds from sale of common stock, gross
Schedule of stock issued under financing transactions [Table Text Block]
Custom Element.
Custom Element.
Custom Element.
Amount due from customers or clients, within one year of the balance sheet date for goods or services that have been delivered or sold in the normal course of business.
Represents details of warrants outstanding, granted, exercised during the period by the reporting entity [Text Block]
Workforce reduction description
Gross proceeds from sale of common stock.
Assets, Current
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Assets
Liabilities, Current
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Cost of Revenue
Selling, General and Administrative Expense
Costs and Expenses
Operating Income (Loss)
Other Expenses
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Preferred Stock Dividends, Income Statement Impact
Shares, Outstanding
Dividends, Preferred Stock
StockIssuedDuringPeriodSharesNewIssues2
StockIssuedDuringPeriodValueNewIssues2
StockIssuedDuringPeriodSharesNewIssues3
StockIssuedDuringPeriodValueNewIssues3
Stock Issued During Period, Value, New Issues
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Increase (Decrease) in Receivables
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Restricted Cash for Operating Activities
Increase (Decrease) in Other Noncurrent Assets
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Deferred Revenue
Increase (Decrease) in Customer Advances
Increase (Decrease) in Deferred Liabilities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Increase (Decrease) in Other Current Assets
Net Cash Provided by (Used in) Investing Activities
Payments of Ordinary Dividends, Preferred Stock and Preference Stock
Repayments of Long-term Capital Lease Obligations
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Inventory, Policy [Policy Text Block]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Schedule of Inventory, Current [Table Text Block]
Operating Leases, Future Minimum Payments Due
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount
Income Tax Expense (Benefit)
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Deferred Tax Assets, Deferred Income
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Liabilities, Property, Plant and Equipment
Deferred Tax Liabilities, Gross
Deferred Tax Assets, Net
Other Receivables
Other Assets
Disposal Group, Including Discontinued Operation, Accounts Payable
Other Accrued Liabilities, Current
Revenue from Contract with Customer, Including Assessed Tax
Dividends, Preferred Stock, Stock